Venetoclax-Obinutuzumab With, Without Ibrutinib Superior in Leukemia

THURSDAY, May 11, 2023 -- For fit patients with chronic lymphocytic leukemia (CLL), venetoclax-obinutuzumab with or without ibrutinib, is superior to chemoimmunotherapy as first-line treatment, according to a study published in the May 11 issue of...